ArticleBritish journal of cancer2026
A panel of four autoantibodies to tumour-associated antigens in patients with prostate cancer and its potential for multi-cancer detection.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGenomic alterations can drive tumorigenesis, and understanding the immune response to those alterations may aid in developing new targets for diagnosis and therapy. Tumour-associated antigens (TAAs) are self-antigens that are abnormally expressed in tumours. Autoantibodies (AAbs) triggered by TAAs have been considered reporters of early carcinogenesis. This study aimed to profile AAbs to overexpressed or driver gene-related proteins (DRPs) in prostate cancer (PCa).
methodsTwenty-nine targets including 14 overexpressed proteins and 15 DRPs were screened via serological proteome analysis and bioinformatics analysis, respectively. ELISA was then performed to assess their corresponding AAbs in 293 serum samples. Immunohistochemistry (IHC) was used to determine the tissue expression of TAAs.
resultsNineteen AAbs showed significantly higher serum levels in PCa patients than in normal controls. A panel with four AAbs (PIK3CA, SPOP, IF4H, HSP60) was developed, showing an AUC of 0.901. A differential AAb response to these four TAAs was observed in three distinct PCa populations. The panel was evaluated across six other common cancers including 445 serum samples, showing potential for multi-cancer detection. High expression of the four TAAs targeted by AAbs was found in PCa tissues by IHC.
conclusionsThese findings suggest that overexpressed proteins or DRPs may have altered immunogenicity, leading to the production of corresponding AAbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.